Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-COVID and EG-COVARo in Healthy Adults
NCT05188469Phase 2Completed
- Sponsor
- EyeGene, Inc.
- Start
- Mar 2022
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EG-COVID in coronavirus disease 2019 (COVID-19), sponsored by EyeGene, Inc.. Started Mar 2022; status: completed.
02
Drugs
EG-COVID
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05188469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05188469.